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Substrate and stereochemical control of peptidoglycan cross-
linking by transpeptidation by Escherichia coli PBP1B 
Anita C. Catherwood$, Adrian J. Lloyd+$, Julie A. Tod, Smita Chauhan@, Susan E. Slade†, Grzegorz P. Walk-
owiak ‡, Nicola F. Galley¶, Avinash S. Punekar§, Katie Smart, Dean Rea#, Neil D. Evans*, Michael J. Chap-
pell*, David I. Roper and Christopher G. Dowson+ School of Life Sciences, University of Warwick, Gibbet Hill Road, 
Coventry, CV4 7AL, UNITED KINGDOM. 
 
ABSTRACT: Penicillin binding proteins (PBPs) catalysing transpeptidation reactions that stabilize the peptidoglycan component of 
the bacterial cell wall are the targets of -lactams, the most clinically successful antibiotics to date.   However, PBP-transpeptidation 
enzymology has evaded detailed analysis, because of the historical unavailability of kinetically competent assays with physiologically 
relevant substrates and the previously unappreciated contribution of protein cofactors to PBP activity.  By re-engineering peptidogly-
can synthesis, we have constructed a continuous spectrophotometric assay for transpeptidation of native or near native peptidoglycan 
precursors and fragments by Escherichia coli PBP1B, allowing us to (a) identify recognition elements of transpeptidase substrates, 
(b), reveal a novel mechanism of stereochemical editing within peptidoglycan transpeptidation, (c) assess the impact of peptidoglycan 
substrates on -lactam targeting of transpeptidation and (d) demonstrate both substrates have to be bound before transpeptidation 
occurs.   The results allow characterization of high molecular weight PBPs as enzymes and not merely the targets of -lactam acyla-
tion. 
INTRODUCTION 
Peptidoglycan is a polymer of alternating N-acetyl glucosaminyl 
(GlcNAc) and N-acetyl muramyl (MurNAc) saccharides ap-
pended to which are penta, tetra or tripeptides, crosslinked to im-
part mechanical rigidity essential for bacterial viability[1].  The 
transpeptidases responsible for these crosslinks, the PBPs, are 
targets of -lactams which were discovered ninety years ago[2], 
and comprise the most clinically valuable antimicrobials[3,4]. -
lactam resistance, due to extended spectrum -lactamases has 
contributed to infections resistant to virtually all clinical antibi-
otics[5], highlighting the necessity for new PBP transpeptidation 
inhibitors. 
PBPs possess an active site serine acylated by the donor pepti-
doglycan pentapeptide, with release of its C-terminal D-alanine.  
This acyl-enzyme reacts with water or an amine of a second pep-
tidoglycan peptide, termed an acceptor, constituting D,D-carbox-
ypeptidation or transpeptidation reactions respectively[6-9].  
Transpeptidase PBPs are mono-functional (Type B) or contain 
additional catalytic sites (Type A) that polymerise by transglyco-
sylation a peptidoglycan lipid-linked precursor[6,7].  In E. coli this 
is undecaprenyl pyrophosphoryl GlcNAc-MurNAc L-alanyl--
D-glutamyl-meso-diaminopimelyl-D-alanyl-D-alanine, (lipid II-
meso-DAP[9]; DAP denotes diaminopimelic acid).  An impedi-
ment to novel targeting of PBPs was the inability to define their 
biochemistry beyond their acylation by -lactams[10] which has 
been pursued without substrates, an omission inconsistent with 
the competition with peptidoglycan precursors that -lactams 
have to overcome in vivo.  PBP substrates have until recently[11,12] 
remained unattainable and are key to understanding and transla-
tional exploitation of -lactam:PBP interactions. 
E. coli possesses three bifunctional type A PBPs, 1A, 1B and 
1C[7].  Without PBP1A or PBP1B, PBP1B or PBP1A respec-
tively, are essential[13-15].   E. coli PBP1B is localised and acti-
vated by the outer membrane protein LpoB[16-18].  Critically, how-
ever, lack of quantitative transpeptidase assays with physiologi-
cal substrates has severely limited analysis of PBP1B transpepti-
dation and translational progress towards its exploitation as an 
antibiotic target.  
Here, we describe an LCMSMS-validated continuous photomet-
ric transpeptidase assay for E. coli PBP1B, which we use to quan-
titate the impact of LpoB on PBP1B and probe transpeptidase 
substrate structure-activity relationships, revealing how stereo-
chemical fidelity of transpeptidation is maintained.  We charac-
terise the impact of peptidoglycan substrates on -lactam-inhibi-
tion of PBP1B suggesting acceptor and donor binding prior to 
transpeptidation, which we confirm by steady state kinetics.   
Therefore, following the ninetieth anniversary of the discovery 
of penicillin[2], we give the most detailed enzymatic account thus 
far of peptidoglycan transpeptidation that is targeted by this most 
clinically essential class of antibiotics.
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Development of a continuous assay for PBP transpeptidation.  
To analyse E. coli PBP1B transpeptidation kinetics, a continuous 
assay for this activity was devised:  D-alanine generated by 
PBP1B was oxidised by D-amino acid oxidase yielding hydrogen 
peroxide which was detected by horseradish peroxidase-cata-
lysed conversion of amplex red to the chromophore resorufin 
(Scheme 1).   
Initial attempts to follow transpeptidation required prohibitive (> 
1 M) amounts of PBP1B.   However, addition of LpoB, allowed 
measurement of  lipid II-meso-DAP and PBP1B-dependent rates 
with < 10 nM PBP1B (Figure 1a), where utilising lipid II-Lys and 
MurNAc L-alanyl--D-glutamyl-meso-DAP-D-alanyl-D-alanine 
(MurNAc meso-DAP pentapeptide), dependence of PBP1B ac-
tivity on LpoB was hyperbolic with a half maximal activation at 
0.26 ± 0.02 M LpoB, and a maximal stimulation of PBP1B of 
1140 ± 20 fold (Figure 1b).   PBP1B activity with lipid II-meso-
DAP was also essentially dependent on LpoB, which activated 
the enzyme >250-fold (Figure 1 bi).  Therefore 1.97 M LpoB 
was included in all assays from hereon.  The assay was linearly 
dependent on E. coli PBP1B, utilising lipid II-meso-DAP or lipid 
II-Lys with MurNAc meso-DAP pentapeptide (Figure 1c). 
We used LCMS and LCMSMS of mutanolysin-digested PBP1B 
products (S.1.2.3.2.1.) to determine if PBP1B-catalysed D-ala-
nine release from lipid II-meso-DAP reported transpeptidation, 
and detected products with m/z values of GlcNAc-MurNAc L-
alanyl--D-glutamyl-meso-DAP-D-alanyl donor bonded via the 
carbonyl of its C-terminal D-alanyl residue to the -amine of the 
meso-DAP of the GlcNAc-MurNAc L-alanyl--D-glutamyl-
meso-DAP-D-alanyl-D-alanine acceptor (Figure 2a).  The mole-
cule fractionated into three anomers (Figure 2c; expected 
(m+2H+)/2 = 966.92, found = 966.91, 966.92 and 966.92). 
LCMSMS of ions eluting at 7.92 minutes (Figure 2d, Table S3) 
confirmed the 966.92 ion was the PBP1B transpeptidation prod-
uct.  Identical fragmentation of 966.92 ions eluting at 7.65 and 
7.31 minutes was also observed.  Higher order products with 
three or four disaccharide peptides linked by transpeptidation 
(expected m+2H+)/2 = 1427.10 and 1887.79 were not detected, 
even if the concentration of PBP1B in the LCMS assays was in-
creased 100-fold to 1 M. 
 D-alanine release could additionally have originated from 
PBP1B-D,D-carboxypeptidation.  LCMS detected the D,D-car-
boxypeptidase-generated tetrapeptide GlcNAc-MurNAc L-ala-
nyl--D-glutamyl-meso-DAP-D-alanine (Figure 2b) as two 
anomer peaks at ~1% of the abundance of the transpeptidation 
product  (Figure 2c), (observed and expected m+H+)/1 both peaks 
= 940.40; Figure S3aii). LCMSMS confirmed both peaks were 
GlcNAc-MurNAc tetrapeptide (Figure S3ai; Table S4), suggest-
ing D-alanine release from lipid II-meso-DAP overwhelmingly 
followed transpeptidation relative to carboxypeptidation.  
 
Scheme 1: Continuous photometric assay of PBP1B transpeptidation.  The 
scheme shows the detection of D-alanine generated in a format where the sub-
strates act exclusively as donor or acceptor.  TG = transglycosylase, TP = trans-
peptidase.  
Refinement of the PBP1B transpeptidation continuous assay 
to distinguish between donor and acceptor utilization.  In E. 
coli peptidoglycan synthesis, lipid II-meso-DAP serves both as 
acceptor   and   donor. Therefore, to study PBP1B transpeptidase 
substrate utilization required exclusive donors and acceptors.  As 
lipid II-Lys is only a donor[19,20] we challenged PBP1B with lipid 
II-Lys which supported low rates of D-alanine release.  Striking 
enhancements of D-alanine release occurred (≥10-fold) when 
MurNAc meso-DAP pentapeptide as acceptor was added (Figure 
1d,e).   
We confirmed the assay followed PBP1B activity showing that 
ampicillin inhibited transpeptidation (Figure 1e).  The drug at 50 
M was without impact on D-amino acid oxidase or horse radish 
peroxidase activity.  Only at 11.5 mM or 14.3 mM ampicillin re-
spectively, was any reduction of oxidase and peroxidase activity 
observed (18.2% and 26% inhibition respectively).   Therefore, 
the impact of the concentrations of ampicillin used hence forth 
on the coupling enzymes could be ignored. 
To establish the coupling system reported PBP1B transpepti-
dation we omitted D-amino acid oxidase from the assay. Its sub-
sequent re-addition caused an instantaneous increase in absorb-
ance, to that had the oxidase always been present (Figure 1f), 
suggesting the assay measured PBP1B transpeptidation, un-influ-
enced by consumption of the D-alanine. (Figure 1f). 
We confirmed enhancement of PBP1B-catalysed D-alanine re-
lease from Lipid II-Lys by MurNAc meso-DAP pentapeptide fol-
lowed transpeptidation by LCMS and LCMSMS:  We detected 
the  transpeptidation  product  GlcNAc-MurNAc  L-alanyl--D- 
glutamyl-L-lysyl-D-alanyl donor stem bonded via the carbonyl 
of the C-terminal D-alanyl to the -amine of the meso-DAP of the 
MurNAc meso-DAP pentapeptide acceptor (Figure S4a,b; ex-
pected/observed (m+2H+)/2 = 843.38/843.38) and confirmed its 
identity by LCMSMS.  (Figure S4c; Table S5). Consistent with 
Figure 1e and[19,20]  we could not detect   lipid II-Lys donor/lipid  
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Figure 1: Characterization of E. coli PBP1B catalysis as reported by D-alanine release.  (a) D-alanine release by PBP1B from lipid II-meso-DAP.  Assay was 
performed with lipid II-meso-DAP or Triton X-100 and 1.97 M LpoB.    Data are mean ± standard deviation (S.D., n=3).  (b)  Dependence of PBP1B D-alanine release 
on LpoB.   11 nM E. coli PBP1B (except at 0 M LpoB where [PBP1B] = 440 nM), were assayed with 20 M lipid II-Lys or 20 l 0.1% (v/v) Triton X-100 (control) 
and  20 M MurNAc meso-DAP pentapeptide or (bi) with 20 M lipid II-meso-DAP ± 4 M LpoB.  Data are mean ± S.D. (n=3). (c)  Dependence of PBP1B D-
alanine release on PBP1B.   Assays containing 1.97 M LpoB and 20 M lipid II-meso-DAP or 20 M lipid II-Lys with 20 M MurNAc meso-DAP pentapeptide were 
initiated by PBP1B, controls replaced lipid II with 20 l 0.1% (v/v) Triton X-100.  (d) D-alanine release by PBP1B from lipid II-Lys with a MurNAc meso-DAP 
pentapeptide acceptor. Assay contained 80M MurNAc meso-DAP pentapeptide acceptor and 1.97 M LpoB, with lipid II-Lys (red data points, maroon error bars) or 
Triton X-100 (blue data points, maroon error bars).  The acceptor was added at zero time.  All points are mean ± S.D. (n = 3).  (e)  Inhibition of PBP1B transpeptidation 
by ampicillin.  Assays contained 20 M lipid II-Lys, 20 M MurNAc meso-DAP pentapeptide acceptor, 1.97 M LpoB, E. coli PBP 1B, with (blue data points maroon 
error bars), or without (red data points, maroon error bars) 50 M ampicillin.  Ampicillin was added at zero time.  Data are mean ± .SD. (n = 3).  (f) Lack of influence of 
D-alanine accumulation by PBP1B on the rate of transpeptidation.  Both assays contained 20 M lipid II-Lys, 1.97 M LpoB and 11 nM E. coli PBP 1B at zero time, 
however only one (red trace) contained D-amino acid oxidase.  At 3.2 minutes, 20 M MurNAc meso-DAP pentapeptide was added to both assays.  At 8 minutes, 33.51 
U.ml-1 Rhodotorula gracilis D-amino acid oxidase was added to the assay from which it had been omitted at time zero (blue trace).  
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Figure 2:  LCMS and LCMSMS analysis of E. coli PBP1B transpeptidation and carboxypeptidation products derived from lipid II-meso-DAP. (a) Structure of 
transpeptidation product resulting from crosslinking of the stem peptides of lipid II-meso-DAP.  Green and blue peptides represent the acceptor and the donor strands 
respectively.  Expected doubly charged m/z ratio is 966.92. (b) Structure of carboxypeptidation product derived from the stem peptide of lipid II-meso-DAP.  Expected 
singly charged m/z ratio is 940.40.  (c)  Extracted ion chromatograms of LCMS analysis of lipid II-meso-DAP transpeptidation.  Red and blue traces following the 
elution of species from a complete E. coli PBP1B assay with m/z ratios of 966.92 and 940.4.  The purple trace is elution of 966.92 m/z species in assays omitting lipid 
II-meso-DAP.  The 7.92, 7.65 and 7.31 minute peaks in the red trace and 7.45 and 7.1 minute peaks in the blue trace are likely anomers of the transpeptidation and 
carboxypeptidation products arising from  muramidase digestion.  The small doublet peak at 7.4 minutes in the purple trace may be due to carryover between samples 
or co-purification of E. coli PBP1B-bound peptidoglycan species. The inset (ci) are the ions of the doubly charged transpeptidation product. (d) LCMSMS fragmentation 
of the 966.92 (m+2H+)/2 transpeptidation product eluting at 7.92 minutes.  All fragment ions were singly charged.  All fragments containing acceptor and donor peptides 
linked by transpeptidation are labelled with purple numbers in yellow squares.  All fragments originating exclusively from only donor or acceptor peptides are labelled 
with yellow numbers in purple squares.  The identity of fragment ions 1 to 44 are displayed in Table S3. 
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II-Lys acceptor transpeptidation product by LCMS (expected 
(m+H+)/1 = 1844.84; (m+2H+)/2 = 922.92, neither found) con-
firming that lipid II-Lys could not act as an acceptor. 
 Without acceptor, PBP1B barely exhibited D,D-carboxypepti-
dase activity with lipid II-Lys spectrophotometrically.  How-
ever this could be detected by LCMS and LCMSMS as Glc-
NAc-MurNAc L-alanyl--D-glutamyl-L-lysyl-D-alanine tetra-
peptide (Figure S5a-d).   MurNAc meso-DAP pentapeptide ab-
lated the tetrapeptide signal (Figure S5b) showing PBP1B min-
imised D,D-carboxypeptidase activity with a competent accep-
tor. 
Lipid II transpeptidase donor polymerization triggers 
transpeptidase activity.  PBP1B transpeptidation is predicated 
by transglycosylation[21-23].  To determine if lipid II polymeriza-
tion or binding triggered transpeptidation we established a mass 
spectrometric assay for transglycosylation as release of un-
decaprenyl pyrophosphate (expected/observed (m-1)/1 of 
925.62/ 925.62) from lipid II-Lys (Figure S6b) which was in-
hibited by 20 M moenomycin as anticipated[21,22,24] (Figure 
S6a).  Furthermore, moenomycin was a tight binding transpep-
tidation inhibitor (IC50 = 12.3 ± 0.9 nM; Figure S6c), confirm-
ing that transglycosylation predicated transpeptidase activity.   
As moenomycin inhibition did not allow us to determine the 
importance of lipid II-Lys glycan chain polymerization to trans-
peptidation, we synthesised methylene lipid II-Lys (Figure S2, 
Tables S1 and S2) where the oxygen between the muramyl 
sugar C-1 and the -phosphorus atom of the undecaprenyl py-
rophosphoryl moiety was now a methylene (Figure S6d).   This 
rendered methylene lipid II-Lys unpolymerisable because, in-
stead of expulsion of undecaprenyl pyrophosphate on transgly-
cosylation as is the case with lipid II-Lys, now polymerization 
by transglycosylation would require expulsion of a carbanion 
which would be chemically highly disfavoured.  Methylene li-
pid II-Lys was not a transpeptidase donor but was inhibitory 
(Figure S6e,f), consistent with polymerization as well as lipid 
II binding being essential for PBP1B transpeptidation.  Congru-
ent with this conclusion was that unpolymerizable candidate do-
nors MurNac meso-DAP pentapeptide, undecaprenyl pyrophos-
phoryl MurNAc L-alanyl--D-glutamyl-L-lysyl-D-alanyl-D-al-
anine (Lipid I-Lys) or undecaprenyl pyrophosphoryl MurNAc 
L-alanyl--D-glutamyl-meso-DAP-D-alanyl-D-alanine (Lipid 
I-meso-DAP), also could not support transpeptidation (Figure 
S7b,c).   
However, these data could not formally distinguish between 
transpeptidation inhibition arising from binding of methylene 
lipid II-Lys to either the transglycosylase or transpeptidase ac-
tive sites of PBP1B.  Therefore, to confirm the essentiality of 
polymerization of lipid II for catalysis of transpeptidation, we 
evaluated the impact of hen egg white lysozyme which cleaves 
the 1-4 linkages between MurNAc-GlcNAc disaccharides of 
peptidoglycan polymers[1] on the transpeptidase activity of 
PBP1B.  Lysozyme was a potent inhibitor of transpeptidase ac-
tivity (Figure S6g), with an IC50 of 2.07 ± 0.09 M (n=3).   This 
observation was consistent with lipid II-Lys polymerization be-
ing a pre-requisite for transpeptidation. 
As PBP1B polymerizes tetrapeptide precursors in vivo[25], 
which would be transpeptidase acceptors, we tested PBP1B 
transpeptidation with MurNac meso-DAP pentapeptide, Lipid 
I-Lys or Lipid I-meso-DAP as monomeric donors with un-
decaprenyl pyrophosphoryl GlcNAc-MurNAc L-alanyl--D-
glutamyl-meso-DAP-D-alanine (Lipid II-meso-DAP tetrapep-
tide; S.1.2.4.2; Tables S1 and S2; Figure S2)  as a polymerisable 
acceptor.  No D-alanine release occurred (Figure S7b,c) sug-
gesting that the necessity for donor polymerization could not be 
supplanted by a polymeric acceptor.  
 To further explore PBP1B transpeptidation with polymerized 
donors, we added lipid II-Lys and Staphylococcus aureus mon-
ofunctional transglycosylase (the activity of which we con-
firmed by SDS-PAGE analysis of polymerization of lipid II-N-
dansyl-Lys; S.1.2.7.; Figure S7d) to assays prior to PBP1B or 
MurNAc meso-DAP pentapeptide.  Considerably less transpep-
tidation was observed (Figure S7a), suggesting PBP1B only ac-
cepted polymeric transpeptidation donor generated on itself. 
Characterization of E. coli PBP1B transpeptidase donor 
and acceptor kinetics and substrate specificity.  The depend-
ence of PBP1B transpeptidation rate on lipid II-meso-DAP was 
sigmoidal, could not be linearised by replotting the data as a 
half reciprocal plot (Figure 3a and insert) or fitted to the Mich-
aelis Menten equation:  
but it could be fitted to an equation describing utilization of two 
moles of substrate/mol enzyme/turnover: 
 This suggested two values of Km (7 ± 3 M and 9 ± 7 M) with 
a kcat of 160 ± 10 min
-1.  LCMS analysis (Figure 2c) argued 
against significant contribution of D,D-carboxypeptidase activ-
ity to these data.  Therefore, these Km values might represent 
lipid II-meso-DAP binding to the transpeptidase donor and ac-
ceptor sites. To explore this further, exclusively donor and ac-
ceptor substrates were required. 
Characterization of transpeptidase donor recognition.  Us-
ing lipid II-Lys as an exclusive transpeptidase donor[19,20] with 2 
mM D-lactate as acceptor, PBP1B transpeptidation was hyper-
bolically dependent on lipid II-Lys (Figure 3b) as was evident 
from the linear half reciprocal plot of the data (Figure 3b insert) 
and fitted the Michaelis Menten equation yielding a Km
App of 8.7 
± 0.6 M and kcat
App of 2.72 ± 0.06 min-1.  This suggested now 
one donor:PBP interaction was required for transpeptidation, 
contrasting with lipid II-meso-DAP utilization, which required 
two such interactions.  Similarly, PBP1B transpeptidation was 
hyperbolically dependent on lipid II-Lys with more complex ac-
ceptors e.g. MurNAc L-alanyl--D-glutamyl-meso- DAP (Mur-
NAc meso-DAP tripeptide; Figure 3c). 
Equation 2 
Equation 1 
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Figure 3:  Dependence of initial rates of D-alanine release from lipid II do-
nors.  Error bars are ± S.D.  of 4 or 3 observations for data in panels (a) and (b)-
(d) respectively.  (a) Dependence of initial rate of D-alanine release by PBP1B 
on lipid II-meso-DAP. Initial rates following A555 were initiated by 5.5 nM 
PBP1B.  Controls replaced lipid with 0.1% (v/v) Triton X-100.  Main panel: 
initial velocity vs [lipid II-meso-DAP], fitted to equation 2 in the text.  Insert is 
the data as a half reciprocal plot ([lipid II-meso-DAP]/vo vs [lipid II-meso-
DAP]).   (b) Dependence of initial rate of transpeptidation between lipid II-Lys 
and D-lactate by PBP1B.   A555 nm was followed and at 2 minutes and 8 minutes, 
5.5 nM PBP1B and 2 mM D-lactate acceptor were added respectively.   Controls 
omitted donor lipid.    Main panel is initial velocity vs [lipid II-Lys], fitted to 
Equation 1in the text.  The insert is the data as a half reciprocal plot.  (c) De-
pendence of initial rate of transpeptidation between lipid II-Lys and MurNAc 
meso-DAP tripeptide by PBP1B.  A555 nm was followed for 2 minutes after which 
time, 9.6 nM PBP1B was added.  A555 nm was followed for a further 6 minutes, 
when lipid II-Lys was then added.  The experiment was carried out at 3.75, 10, 
12.5 and 60 M MurNAc meso-DAP tripeptide acceptor.  Controls omitted ac-
ceptor.  Data were fitted to equation 1 in the text.  (d) Dependence of initial rate 
of D-alanine release by PBP1B on lipid II-L,L-DAP. Initial rates followed as 
A555were initiated by 6.2 nM PBP1B.  Control assays replaced the lipid substrate 
with 0.1% (v/v) Triton X-100.  Main panel is initial velocity vs [lipid II-L,L-
DAP], fitted to equation 1 in the text.  The insert is the data as a half reciprocal 
plot. 
To further probe transpeptidase donor recognition, we synthe-
sised lipid II-Lys analogues where N-biotinyl L-lysine, N-dan-
syl L-lysine, N-methyl L-lysine, 5-hydroxy L-lysine or L-argi-
nine replaced lysine (S.1.2.4.1; Tables S1 and S2, Figure S1). 
All lipids were donors (Figure S8).  Lipid II-Arg and lipid II-
N-biotinyl-Lys were at least as active as lipid II-Lys as donors.  
However, methylation, hydroxylation or dansylation of the do-
nor lysine attenuated activity 
E. coli PBP1B transpeptidase donor recognition depends 
upon the glutamyl--carboxyl.  To characterize PBP1B donor 
recognition, we replaced D-glutamate of lipid II-Lys with D-
iso-glutamine (amidated lipid II-Lys, S.1.2.4.1; Tables S1 and 
S2, Figures S1 and S9a) as found in Gram positive organ-
isms[26].  As a PBP1B transpeptidase donor, amidated lipid II-
Lys failed to support activity (Figure S9b) suggesting the glut-
amyl carboxyl was a key recognition element. Consequently, 
we established mass spectrometrically that amidated-lipid II-
Lys supported transglycosylase activity (Figure S9c and d).  
Thus, the -glutamyl carboxyl was key for transpeptidase donor 
recognition. 
E. coli PBP1B transpeptidase donor recognition is stereo-
selective for the fifth position D-alanine.  To probe PBP1B 
transpeptidation stereochemistry at the donor C-terminus, we 
attempted, but failed to continuously couple L-alanine release 
from transpeptidation between lipid II-Lys with an L-alanyl--
D-glutamyl-L-lysyl-D-alanyl-L-alanine stem peptide (Lipid II-
Lys (L-Ala) S 1.2.4.1; Tables S1 and S2, Figure S1) and Mur-
NAc meso-DAP pentapeptide to alanine racemase (Figure 
S10c), despite the ability of PBP1B to polymerise this donor by 
transglycosylation (Figure S10a,b). Similarly, Lipid II-Lys (L-
Ala) did not inhibit PBP1B transpeptidation (Figure S10c).  To 
enhance assay sensitivity we reacted PBP1B with lipid II-Lys 
(L-Ala) for an hour prior to L-alanine assay.  However, this ap-
proach failed to detect L-alanine release although D-alanine re-
lease from lipid II-Lys was detectable in this manner (Figure 
S10di and S10dii). This suggested donor recognition required a 
C-terminal D-stereo-centre. 
Stereoisomerization of the -carboxyl of the donor meso-
DAP residue stimulates E. coli PBP1B carboxypeptidase ac-
tivity.   Although we showed the -DAP carboxyl is dispensable 
for transpeptidase donors of E. coli PBP1B (Figure 1d,e), its 
stereochemistry profoundly affects peptidoglycan structure[27].  
Therefore, we determined if lipid II-L,L-DAP, the stereoisomer 
of lipid II-meso-DAP was a transpeptidase donor.  Lipid II-L,L-
DAP (S.1.2.4.1; Table S1 and S2; Figure S1) supported rapid 
acceptor-independent evolution of D-alanine.  We confirmed 
this with lipid II-L,L-DAP synthesised using meso-DAP dehy-
drogenase (S.1.2.4.1), to discount lipid II-meso-DAP contami-
nation.  PBP1B-catalysed D-alanine release kinetics were now 
hyperbolically dependent on lipid II-L,L-DAP (Figure 3d and 
insert) and could be explained by one Km value, whereas those 
of lipid II-meso-DAP involved two such values. 
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Was PBP1B now acting as a D,D-carboxypeptidase ?  Exami-
nation of  the products formed by PBP1B from lipid II-L,L-DAP 
and lipid II-meso-DAP by LCMS and LCMSMS showed a 
6.44-fold increase in the rate of synthesis of D,D-carboxypepti-
dase product GlcNAc-MurNAc L-alanyl--D-glutamyl-DAP-
D-alanine from lipid II-L,L-DAP (Figure 4b, confirmed by 
LCMSMS, Figure S3b; Table S4) relative to that of lipid II-
meso-DAP.  Concurrently there was an 8.8 fold decrease in the 
initial rate of transpeptidation (Figure 4a).  LCMSMS (Figure 
S11a; Table S3) confirmed the residual transpeptidation of lipid 
II-L,L-DAP.  This represented a 57-fold increase in the carbox-
ypeptidation to transpeptidation ratio on inversion of the lipid 
II-DAP -carbon from a D to an L configuration. 
If L,L-containing donors biased E. coli PBP1B towards D,D-
carboxypeptidation, we speculated the donor peptide L,L- DAP 
L--amino group might react with the ester between the E. coli 
PBP1B transpeptidase active site serine and the donor tetrapep-
tide.  Therefore we assessed the impact of N-acetylation of the 
DAP -amino group of lipid II-L,L-DAP (termed lipid II-L,L-
NAc-DAP; S.1.2.4.1; Table S1 and S2; Figure S1) on PBP1B 
activity.  D-Alanine release now depended upon MurNAc 
meso-DAP pentapeptide as an acceptor suggesting suppression 
of D,D-carboxypeptidase with restoration of transpeptidase ac-
tivity.   The transpeptidation rate (20 M both substrates, 38 ± 
3 min-1 (n = 3)) compared favourably with rates determined 
identically with 20 M lipid II-Lys and MurNAc meso-DAP 
pentapeptide (27 ± 2 min-1 n=3).   
Restoration of transpeptidation by lipid II-L,L-DAP N-acetyla-
tion was confirmed by LCMS (Figure 4c and cii).  We detected 
the lipid II-L,L-NAc.DAP/MurNAc meso-DAP pentapeptide 
transpeptidation product: GlcNAc-MurNAc L-alanyl--D-glu-
tamyl-L,L-Nac-DAP-D-alanyl donor stem linked to the -
amine of the meso-DAP of the MurNAc meso-DAP pentapep-
tide acceptor (expected/observed (m+2H+)/2 = 886.38/ 886.38, 
for all anomer peaks).  We also observed the corresponding 
product of lipid II-meso-NAc-DAP (S.1.2.4.1; Table S1 and 
S2; Figure S1) and MurNAc meso-DAP pentapeptide (Figure 
4c and ci; (expected/observed (m+2H+)/2 = 886.38/886.38, for 
all anomer peaks). LCMSMS confirmed the structure of the li-
pid II-L,L-NAc.DAP/MurNAc meso-DAP pentapeptide trans-
peptidation product (Figure S11b; Table S7).  These data sug-
gested orientation of the -amino group of the DAP moiety con-
trolled the catalytic pathway(s) followed by the PBP1B trans-
peptidation site. 
Characterization of transpeptidase acceptor recognition by 
truncation of the structure of Lipid II-meso-DAP.  All ac-
ceptor (Table S1, S2 and Figure S2) dependencies of activity 
were hyperbolic (Figure S12a-j).   Although the precision of the 
estimates of acceptor Km and consequently kcat/Km for lipid II-
meso-DAP (9 ± 7 M and 20 ± 10 min-1.M-1 respectively) was 
low, all acceptors containing meso-DAP were significantly ac-
tive where truncation of lipid II-meso-DAP acceptor to Lipid I-
meso-DAP and MurNAc meso-DAP pentapeptide respectively 
reduced the kcat
App/Km
App 8 ± 6- and 6 ± 5-fold (Table 1).  C-
terminal D-alanine deletion from lipid II-meso-DAP or Mur-
NAc meso-DAP pentapeptide to generate Lipid II-meso-DAP 
tetrapeptide or MurNAc L-alanyl--D-glutamyl-meso-DAP-D-
alanine (MurNAc meso-DAP tetrapeptide), caused a 4 ± 2 - or 
3 ± 2-fold drop in kcat
App/Km
App respectively relative to that of 
lipid II-meso-DAP (Table 1).    Truncation of Lipid II meso-
DAP to MurNAc meso-DAP tripeptide, reduced the 
kcat
App/Km
App for this substrate 8 ± 6-fold relative to that of lipid 
II-meso-DAP (Table 1). Truncation to MurNAc L-alanyl--D-
glutamate (MurNAc L-Ala--D-Glu) inactivated the acceptor, 
consistent with loss of the meso-DAP -amino group. 
The D-alanine analogues D-lactate (Table 1, Figure S12(i)) and 
the antibiotic D-cycloserine were acceptors that exchanged the 
donor C-terminal amino acid of lipid II-Lys from D-alanine to 
a D-lactyl or D-cycloseryl moiety.  The kcat
App/Km
App for D-lac-
tate dropped 3000 ± 2000-fold relative to that of lipid II-meso-
DAP (Table 1).  The D-cycloserine transpeptidase kinetics re-
quired substitution of Rhodotorula gracilis D-amino acid oxi-
dase with the porcine kidney enzyme to reduce control rates in 
the presence of D-cycloserine to tolerable levels.  Now, we were 
able to obtain rates at 50 M and 100 M   D-cycloserine 
(which were inhibited by 50M moenomycin) to generate pre-




App of 5.79 min-
1, 64.3 M and 0.090 min-1M-1 respectively, suggesting D-cy-
closerine was 20-fold more efficient than D-lactate as an accep-
tor, albeit that lipid II-meso-DAP was by far the preferred sub-
strate (Table 1).    That lipid II-Lys (L-Ala) was not a PBP1B 
donor led us to test L-alanine as an acceptor, where we observed 
the kcat
App/Km
App for this L-amino acid to be 13 ± 1-fold lower 
than that of D-lactate (Table 1; Figure S12i,j). 
 Identification of the -carboxyl of the meso-DAP residue as 
an essential peptidoglycan acceptor recognition element. 
The majority of recognition of the acceptor lay between the mu-
ramyl and diaminopimelyl moieties.  Therefore, were the D-
glutamyl -carboxyl or meso-DAP -carboxyl groups of the 
stem peptide acceptor recognised by PBP1B?  Considering 
kcat
App/Km
App values, substitution of iso-glutaminyl for isoglu-
tamyl residues (denoted with the suffix NH2) within any Mur-
NAc meso-DAP acceptor (S.1.2.4.2; Tables S1 and S2; Figure 
S2) did not substantially affect PBP1B transpeptidation (Table 
1; Figure S12c-h).  Therefore, the -glutamyl carboxyl negative 
charge was not recognised.  Consistent with this, MurNAc di-
peptide was not a PBP1B inhibitor.  To probe the contribution 
of the meso-DAP -carboxyl to acceptor recognition, transpep-
tidation of lipid II-Lys with lipid I-Lys as acceptor was assayed.  
Unlike lipid I-meso-DAP, lipid I-Lys was unreactive, illustrat-
ing the importance of the meso-DAP -carboxyl in transpepti-
dase acceptor recognition. 
We further probed the impact of acceptor DAP-carboxyl and 
amino group stereochemistry on transpeptidation.  Lipid II-L,L-
DAP tetrapeptide was not active as an acceptor at 20µM (Figure 
4d), whereas  lipid II-meso-DAP tetrapeptide was (Figure 4e). 
LCMS (Figure 4f) showed formation of the transpeptidation 
product GlcNAc-MurNAc L-alanyl--D-glutamyl-L-lysyl-D- 
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Figure 4:   Analysis of the effect of donor and acceptor DAP stereoisomerization on E. coli PBP1B transpeptidation and carboxypeptidation.    (a) LCMS time 
course of transpeptidation or (b) carboxypeptidation of lipid II-meso or L,L-DAP. 9.6 nM PBP1B was incubated with 20 M lipid II meso or L,L-DAP.  Products were 
digested and subjected to LCMS (S.1.2.3.2.1).  Peak areas from extracted ion chromatograms for the transpeptidase or carboxypeptidase products ((m+2H+)/2 = 996.92 
or (m+H+)/1 = 940.40) were plotted vs. time. (c)  LCMS of PBP1B transpeptidation with MurNAc meso-DAP pentapeptide acceptor and lipid II-meso or L,L-NAc-DAP. 
9.6 nM PBP1B was incubated ±20 M MurNAc meso-DAP pentapeptide ± 20 M lipid II-meso- or L,L-NAc-DAP.  –lipid II controls replaced the lipid with hexa-
ethylene glycol dodecyl ether (E6C12).  Transpeptidase product extracted ion chromatograms ((m+2H
+)/2 = m/z of 886.38) are shown: MurNAc meso-DAP pentapeptide 
alone; E6C12 alone; Lipid II-meso-NAc DAP + MurNAc meso-DAP pentapeptide or Lipid II-L,L-NAc DAP + MurNAc meso-DAP pentapeptide.  (ci)  and (cii): 
Transpeptidation product mass spectra (expected (m+2H+)/2 for meso and L,L species = observed = 886.38).  (d) D-alanine release from lipid II-Lys donor using Lipid 
II-L,L-DAP tetrapeptide or (e) Lipid II-meso-DAP tetrapeptide as acceptor. 20 M lipid II-Lys (purple trace) or Triton X-100 (blue trace) was added at zero minutes. 
6.17 nM PBP1B and 20 M lipid II-L,L- or meso-DAP tetrapeptide (denoted as Lipid II LL-DAP-4P or Lipid II-meso-DAP-4P) or 0.1% (v/v) Triton X-100 was added 
as indicated.   A555 was followed.  (f)  LCMS of transpeptidation with lipid II-DAP tetrapeptide and lipid II-Lys:  9.6 nM PBP1B was incubated with 20 M lipid II-
meso-or L,L-DAP tetrapeptide and 20 M lipid II-Lys.   LCMS (S.1.2.3.2.1) followed elution of 909.40 m/z (expected (m+2H+)/2 for the transpeptidase product).  
Controls + PBP1B alone (trace E6C12), - acceptor (trace +Lipid II-Lys), or complete reactions (traces Lipid II-Lys + Lipid II-meso-DAP 4P or Lipid II-Lys + Lipid II-
L,L-DAP 4P)  are shown.  Transpeptidation product anomer retention times are in red.  (4fi) is the mass spectrum of the meso-DAP transpeptidation product (exp. 
(m+2H+)/2 for meso and L,L species = that observed for both = 909.40). 
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Figure 5:  -lactam and donor analogue inhibition and steady state kinetics indicate simultaneous binding of donor and acceptor occurs prior to E. coli PBP1B 
transpeptidation. Errors are ± S.D. (n=3) for data in panels (a)-(h).  Panel (a) Impact of donors and acceptors on PBP1B inactivation by ampicillin.   Assays contained 
all components except PBP1B, lipid II-Lys and acceptor.  Parallel assays were run without ampicillin.  Remaining activity at 555 nm was followed after the last (8 
minute) addition: Preincubation with lipid II donor (maroon trace):  20 M lipid II-Lys, 8.49 nM PBP1B and 10 M MurNAc meso-DAP tripeptide were added at 0, 
2 and 8 minutes respectively.   Preincubation with MurNAc meso-DAP tripeptide acceptor (blue trace):  10 M MurNAc meso-DAP tripeptide, 8.49 nM PBP1B and 
20 M lipid II-Lys donor were added at 0, 2 and 8 minutes respectively.   Preincubation without substrate (red trace):  8.49 nM PBP1B was added at 2 minutes.  20 
M lipid II-Lys and 10 M MurNAc meso-DAP tripeptide were added simultaneously at 8 minutes.  Panel (b) Impact of lipid II-Lys donor on inhibition of PBP1B by 
methylene lipid II-Lys.  All components except PBP1B and MurNAc meso-DAP pentapeptide were present at time zero.  At 2 and 8 minutes, 9.6 nM PBP1B and 20 M 
MurNAc meso-DAP pentapeptide were added to initiate transpeptidation.    Panel (c) Impact of MurNAc meso-DAP pentapeptide acceptor on inhibition of E. coli 
PBP1B by methylene lipid II-Lys.  All components excluding PBP1B and MurNAc meso-DAP pentapeptide were present at time zero.  At 2 and 8 minutes, 9.6 nM 
PBP1B and MurNAc meso-DAP pentapeptide were added to initiate transpeptidation.  Panels (d) to (g) Double reciprocal plot of the impact of lipid II-Lys donor on the 
dependence of E. coli PBP1B transpeptidation on MurNAc meso-DAP tripeptide.   At 2 and 8 minutes, 9.6 nM PBP1B and 7.5-80 M MurNAc meso-DAP tripeptide 
were added to initiate transpeptidation with 5-60 M lipid II-Lys.  Data (initial velocity (vo) vs [MurNAc meso-DAP tripeptide] at constant [lipid II-Lys]) were globally 
fitted to equations describing an ordered rapid equilibrium mechanism with MurNAc meso-DAP tripeptide as the first binding substrate (Panel d), a ping pong mechanism 
with lipid II-Lys as the first substrate (Panel e),  an ordered rapid equilibrium mechanism with lipid II-Lys as the first binding substrate (panel f) and a random rapid 
equilibrium mechanism (Panel g) (Equations S3, S4, S2 and 3 respectively; Figure S13).  Double reciprocal relationships were then calculated from these fits and 
superimposed over the data. Panel (h) Initial velocity data superimposed over theoretical curves of vo vs. [MurNAc meso-DAP tripeptide] at various [lipid II] computed 
with Equation 3 and corresponding constants in the text. 
alanyl donor linked to the -amine of the meso-DAP of the ac-
ceptor GlcNAc-MurNAc L-alanyl--D-glutamyl-meso-DAP- 
D-alanine (expected/ observed (m+2H+)/2 = 909.40/ 909.40, for 
all three anomer peaks).  In contrast, virtually no product was 
generated from lipid II-L,L-DAP tetrapeptide acceptor con-
sistent with the spectrophotometric data (Figure 4d,e), showing 
a D-configured DAP -carboxyl was essential for transpepti-
dase acceptor recognition.  
Response of transpeptidation to -lactam challenge suggests 
donor and acceptors bind to PBP1B independently.   PBP1B 
is inactivated by -lactam acylation of the transpeptidase active 
site serine[22,24].   Ampicillin inhibited PBP1B transpeptidation 
with an IC50 of 1.27 ± 0.06 M which was increased to 26 ± 2 
M by pre-incubation with 20 M lipid II-Lys donor, and to 4.1 
± 0.3 M by pre-incubation with 20 M MurNAc meso-DAP 
tripeptide acceptor (Figure 5a; chosen as unlikely to compete 
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with the -lactam for the donor site due to truncation of D-ala-
nyl-D-alanine).  Protection of transpeptidation from -lactam 
inhibition by either substrate suggested independent transpepti-
dase donor or acceptor site binding by lipid II-Lys (or its poly-
mer) and MurNAc meso-DAP tripeptide. 
PBP1B inhibition by a non-hydrolysable analogue of lipid 
II-Lys confirms binding of donor and acceptor to form a 
ternary complex with PBP1B.  The ampicillin IC50 experi-
ments suggested PBP1B bound both substrates.  We used meth-
ylene lipid II-Lys as a donor analogue to confirm this result.  
Methylene lipid II-Lys was an inhibitor of transpeptidation with 
an IC50 of 0.9 ± 0.2 M, 18.8 ± 0.8 M and > 20 M at 4, 20 
and 60 M lipid II-Lys respectively (Figure 5b).  Thus the ana-
logue competed with the donor for the transglycosylase and (al-
beit indirectly) for the transpeptidase sites of PBP1B.  However, 
at 4, 20 and 60 M MurNAc meso-DAP pentapeptide, respec-
tive IC50 values for methylene lipid II-Lys were 17 ± 5 M, 12 
± 5 M and 7.8 ± 0.9 M (Figure 5c), suggesting mixed or un-
competitive inhibition by the analogue, that the acceptor bound 
PBP1B with or without lipid II-Lys donor at the transglycosyl-
ation site and that acceptor and donor could simultaneously bind 
PBP1B. 
PBP1B employs a sequential transpeptidase mechanism 
with a ternary complex of donor, acceptor and PBP1B.  
MurNAc meso-DAP tripeptide acceptor bound to PBP1B with-
out the donor (Figure 5a), consistent with donor and acceptor 
binding the active site prior to D-alanine release through donor 
acylation of the PBP[28].  We therefore examined the relation-
ship between initial velocity of transpeptidation and donor con-
centration between 5 and 60 M lipid II-Lys at MurNAc meso-
DAP tripeptide acceptor concentrations between 7.5 and 80 
M.   
Plots of velocity versus MurNAc meso-DAP tripeptide concen-
tration at each lipid II-Lys donor concentration were hyper-
bolic.   Fitting of the data to equations 3 and S2-4 by global non-
linear regression using MATLAB 2017a (S.1.2.8.; Table S8) al-
lowed rejection of equations describing rapid equilibrium Bi Bi 
ordered mechanisms where the acceptor bound before the donor 
(Equation S3; sum of squared errors; SSE,  was 4547.84) and 
Ping Pong (Equation S4; SSE = 4021.19) mechanisms, where 
the most appropriate models based upon the SSE and the model 
correlation coefficient was a Bi Bi rapid random equilibrium 
mechanism (Equation 3; SSE = 2409.5; r2 = 0.94) and an or-
dered rapid equilibrium mechanism (Equation S2; SSE = 
2458.93; r2 = 0.94; Table S8). The selection of these equations 
as most appropriate models of PBP1B transpeptidase kinetics is 
discussed further in S.2.3. 
Visual inspection of the fits by plotting theoretical relationships 
of velocity vs.  MurNAc meso-DAP tripeptide concentration 
(Figures S13 and 5h) and reciprocals thereof (Figures 5d-g) cal-
culated from the constants extracted by global non-linear re-
gression suggested the random rapid equilibrium model to be 
preferable over the other three models.  However, statistically, 
MATLAB could not distinguish between the rapid equilibrium 
or ordered (donor first) model as SEE and r2 parameters for both 
fits were essentially identical (Table S8).  Nevertheless, our am-
picillin and methylene lipid II-Lys inhibition data (Figure 5a-c) 
suggested independent binding of both acceptor and donor to 
the enzyme, and therefore equation 3 describing a random rapid 
random equilibrium mechanism[28] was deemed to be the most 
appropriate descriptor of the relationship between initial veloc-
ity of PBP1B transpeptidation and donor lipid II-Lys and Mur-
NAc meso-DAP tripeptide concentrations (Figure 5h).    
In equation 3, KLII and KM3P are the dissociation constants of 
donor and acceptor in the absence the co-substrate,  is the fac-
tor by which KLII and KM3P were modified by the co-substrate 
and Vmax was the maximal velocity at infinite donor and accep-
tor concentration.  Values were: kcat = 84 ± 5 min
-1, KLII = 25 ± 
6M, KM3P = 130 ± 80 M, and  = 0.13 ± 0.09 M.    It should 
be noted however, that operation of either a Bi Bi random rapid 
equilibrium mechanism or an ordered Bi Bi steady state mech-
anism[28] could not be distinguished as these mechanisms share 
the same form of rate equation. 
 
DISCUSSION 
This paper describes the transpeptidation enzymology of E. coli 
PBP1B employing a kinetically competent continuous assay 
with polymerizable peptidoglycan substrates or fragments 
thereof that is sensitive, straightforward, robust, can character-
ize acceptor and donor-dependent kinetics and was validated by 
LCMS and LCMSMS.  Importantly, this assay is of potential 
utility for 4,3- and 3,3-crosslinking transpeptidases[29], does not 
rely on laborious product purification[22,30-32], unnaturally reac-
tive substrates[21,33] or unphysiological fluorescent substrates 
yielding uncharacterized products[34,35]. Two available radio-
chemical transpeptidation assays using natural substrates em-
ploy digestion of transpeptidation products followed either by 
HPLC[22] or SDS-PAGE[32] fractionation.  Neither monitor PBP 
activity quantitatively compared to the assay reported here. 
If PBP1B was incubated with donor, which it had the oppor-
tunity to polymerise by transglycosylation, the assay entered 
steady state immediately on addition of acceptor, (e.g. Figures 
1e,f and 4e).  Conversely, there was a discernible lag if the re-
action was initiated by addition of donor (Figure 1a, 1d), which 
probably related to the time taken to accumulate polymer at the 
transpeptidase active site.  Any pre-steady state lag accounted 
for consumption of less than 5% of the donor substrate in assays 
performed in this manner and therefore, initial rates were meas-
ured from the subsequent onset of steady state.   
We observed low back ground rates of resorufin production in 
the presence of exclusive donor substrates such as lipid II-Lys, 
which comprised of mostly residual D,D-carboxypeptidase ac-
tivity (e.g. Figure 1e and f).  However even lower rates of ab-
sorbance change in the presence of ampicillin or just Triton X-
100, or without D-amino oxidase (Figures 1d,e and f) were also 
observable, which could be attributable to back ground levels 
of auto-oxidation of amplex red[36]. 
Equation 3 
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Table 1: Specificity and kinetics of dependence of E. coli PBP1B transpeptidation on acceptor concentration.  Assays were performed (Methods) with 1.97 M 
LpoB.  Where the substrate was lipid II-meso-DAP, the donor and acceptor concentrations were initially identical and data were fitted to Equation 2 in the text.  Where 
lipid II-meso-DAP dependence was followed, control assays replaced lipid by 0.1% (v/v) Triton X-100.  For all other acceptors, donor (20 M lipid II-Lys) was added 
first, followed by PBP1B, followed by acceptor.  Controls omitted donor at each [acceptor] and rates were fitted to Equation 1 in the text.  Assays were performed in 
triplicate or quadruplicate (column n).  Goodness of fit was quantified by correlation coefficient (r2).  Standard deviations for kcat
App/Km
App ratios were computed as in[64]
Our lipid II meso-DAP transpeptidation assay was directly pro-
portional to PBP1B between 4-210 nM (Figure 1c).  This was 
surprising because dimerization of PBP1B was previously ob-
served with a KD of 127 nM
[22] (despite contradiction of this 
observation by seven crystal structures from two independent 
investigations[24,37]).  The dimeric PBP1B transpeptidation ac-
tivity was found to be greater than that of the monomeric pro-
tein[22] which would have been expected to cause the relation-
ship between transpeptidation activity and protein concentra-
tion to deviate from the linearity seen in Figure 1c.  However, 
the observations in[22] were made without substrates or LpoB, 
whereas our data was acquired with them and may not be com-
parable.   Previously, activation of PBP1B transpeptidation by 
LpoB was reported as being less than two-fold[16-18,23,38].   How-
ever, the essentiality of LpoB in the absence of PBP1A or 
LpoA in vivo[16,17] was therefore inconsistent with its reported 
modest impact in vitro, which could be achieved in vivo by 
changes in PBP1B expression.   Nevertheless, we have shown 
LpoB-activation of PBP1B great enough (Figure 1b), to be 
consistent with the in vivo essentiality of LpoB.   The discrep-
ancy between our LpoB data and[16-18,23,38] is likely because[16-
18,23,38] did not follow initial rates, and so significantly underes-
timated LpoB-activation. 
 The only transpeptidase products detectable by LCMS and 
LCMSMS were dimeric donor:acceptor pairs.  No lipid II 
meso-DAP transpeptidation products where three or four di-
saccharide peptides were linked were detected, even when car-
ried out with one hundred times (1 M) the amount of PBP1B 
used in the spectrophotometric assay.  Previously, radiochem-
ical HPLC-based assays detected these species as minor prod-
ucts by employment of micromolar PBP concentrations[8,22], 
however these assays were conducted over one hour, whilst 
our data was acquired from within the first 20 minutes of reac-
tion, which may account for our inability to detect tri or tetram-
eric transpeptidation products. 
Our non-polymerizable lipid II-Lys analogue - methylene lipid 
II-Lys bound PBP1B without transpeptidation (Figure S6e,f), 
indicating polymer extension predicated transpeptidation.  We 
confirmed this finding by demonstrating the inhibition of 
transpeptidation by digestion of polymerised lipid II with ly-
sozyme (Figure S6g).  Methylene lipid II-Lys was a less potent 
inhibitor than moenomycin possibly because the latter mimics 
binding of a tetrasaccharide, making extensive interactions 
with residues in and beyond the transglycosylase donor site[24] 
whilst our analogue mimics only disaccharide binding to the 
transglycosylase acceptor site of PBP1B.  Interestingly, pre-
polymerised transpeptidase donor did not support transpepti-
dation (Figure S7a) suggesting glycan polymer passage be-
tween transglycosylation and transpeptidation sites was only 
accessible by glycan polymerized on enzyme.  This was con-
sistent with[39] and[40] where lipid II polymerization by PBP1B 
in sphaeroplasts did not require polymeric peptidoglycan pri-
mer because of the ability of PBP1B to polymerize glycan 
chains de novo[22].  
The efficiency of PBP1B lipid II meso-DAP transpeptidation 
(Table 1) was comparable with other peptidoglycan synthetic 
enzymes[41-45].  Thus PBP1B transpeptidation is unlikely to 
limit peptidoglycan synthesis. Crosslinking frequency in pep-
tidoglycan[46] and PBP1B transpeptidation rates relative to 
transglycosylation[22] suggest the latter does not rate-limit the 
former.  This agrees with our data and[24] where PBP1B 
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transglycosylation depends sigmoidally upon lipid II-Lys.  If 
transglycosylation limited transpeptidation, sigmoid lipid II-
Lys kinetics would characterize transpeptidation.  However, 
this relationship was hyperbolic (Figure 3b,c) suggesting no 
such limitation, consistent with[22,24,46].   Hence the lipid II-
meso-DAP kinetics in Figure 3a reflect transpeptidation of an 
identical acceptor and donor.  
We identified the donor glutamyl--carboxyl as a PBP1B 
recognition element (Figure S9) in contrast to Streptococcus 
pneumoniae PBPs where -amidation of D-glutamyl is recog-
nised[35]. Like PBP1B, E. coli PBP6[47] similarly interacts with 
the donor -glutamyl carboxyl.  Donor stem peptide third po-
sition recognition was less specific. Various N acyl-lysines 
could replace meso-DAP showing its D--amino group was not 
recognised (Figure S8).  Similarly, E. coli PBP6 had no inter-
action with the stem peptide lysine[47].  Acceptance of donors 
with L-lysine or L-arginine by PBP1B highlights the role of E. 
coli MurE, barring L-lysine or L-arginine incorporation into 
peptidoglycan in favour of meso-DAP[43,46,48,49].   
Like Streptomyces R61 transpeptidase[50], E. coli PBP1B 
strongly discriminated against lipid II-Lys (L-Ala) or L-alanine 
as a donor or acceptor (Figure S10c,d(i)), suggesting the D- 
configuration of the donor C- and acceptor N-terminii was 
strongly favoured.  Streptomyces R61 D,D-transpeptidase and 
E. coli PBP6 bind the substrate C-terminal D-alanine through 
numerous hydrogen bonds[47,51]  congruent with the stereo-se-
lectivity of E. coli PBP1B.  Our synthesis of lipid II-Lys (L-
Ala) (S.1.4.2.1., Tables S1 and S2, Figure S1) showed pepti-
doglycan precursor synthesis could be corrupted by D-alanyl-
L-alanine in vitro.  The failure of E. coli PBP1B transpeptidase 
to interact with lipid II-Lys (L-Ala) and the fidelity of D-ala-
nine-D-alanine ligase that precludes D-alanyl-L-alanine gener-
ation[52] may prevent corruption of peptidoglycan synthesis in 
vivo.   
D-lactate and D-cycloserine were more efficient PBP1B ac-
ceptors than L-alanine (Table 1, Figure S12i,j). D-cycloserine 
utilization was curious, as there is no free -carboxyl adjacent 
to the amine nucleophile of this molecule, which we had 
shown here to be a PBP1B acceptor recognition element. How-
ever, D-cycloserine utilization by Streptomyces D,D-transpep-
tidases is known[53,54] where it was accounted for by virtue of 
an appreciable negative charge on the carbonyl oxygen of the 
molecule  to its free amino group[54].  This would endow the 
antibiotic with -amino acid-like properties explaining its 
recognition as an acceptor by PBP1B.  The ability of PBP1B 
to utilise D-cycloserine may enhance -lactam lethality by cor-
rupting transpeptidation or preventing peptidoglycan precursor 
synthesis[55].     
Lipid I meso-DAP was an E. coli PBP1B transpeptidation ac-
ceptor (Table 1, Figure S12a) but cannot be transglycosylated.  
Thus the lipid II flippase has to avoid lipid I meso-DAP 
transport to the outer face of the cell membrane to forestall 
competition with peptidoglycan acceptor strands for transpep-
tidation which would weaken peptidoglycan.  MurJ/FtsW 
specificity is unknown[56] but may be important because  the E. 
coli lipid I-meso-DAP : lipid II-meso-DAP ratio is 7:2[57].   
The only PBP1B acceptor peptide element recognised was the 
meso-DAP carboxyl, consistent with accumulation of uncross-
linked lysine-containing stem peptides on S. aureus MurE 
over-expression in E. coli[19].  Our data and[19]  suggest pepti-
doglycan disruption through replacement of meso-DAP with 
lysine could be avoided by discrimination against lysine-con-
taining acceptors by PBP1B and other PBPs.   
The correct orientation of the DAP acceptor -carboxyl was as 
essential here (Figure 4d,e), as it is in vivo for transpepti-
dation[27].  The meso to L,L re-orientation of the donor DAP -
amino group might facilitate binding of water between it and 
the PBP1B-esterified carbonyl of the donor D-alanyl residue, 
promoting carboxypeptidation (Figure 4b, S3a, Table S4).  
Consistent with this, E. coli PBP5 may use water to protonate 
D-alanine during D,D-carboxypeptidation[58].  That lipid II 
L,L-DAP -N-acetylation restored donor transpeptidation 
(Figure 4c, S11b, Table S7) indicated orientation of this amine 
and/or a water might control the PBP1B transpeptidation:car-
boxypeptidation ratio.  Discrimination of PBP1B against 
crosslinking L,L-DAP-peptides might ensure L,L-DAP resi-
dues evading MurE specificity would be uncrosslinked, pre-
serving D,D-stereochemistry of 4,3 peptidoglycan crosslink-
ing and cell wall structure.  We propose lipid II L,L-DAP en-
hancement of carboxypeptidation and discrimination against 
L,L-DAP acceptors constitutes an editing mechanism main-
taining peptidoglycan stereochemistry if MurE fails to exclude 
L,L-DAP[27]. 
Peptidoglycan synthesis is targeted by -lactam-acylation of 
PBPs[3,4].  Here, lipid II-Lys protected E. coli PBP1B transpep-
tidation from ampicillin (Figure 5a), suggesting -lactam sen-
sitivity was attenuated by peptidoglycan precursor competition 
for the PBP1B transpeptidation site.  Consistent with this is 
donor-promoted relief of Streptomyces R61 D,D-carboxypep-
tidase-transpeptidase penicillin V inhibition[59].  Also relevant 
is the penicillin tolerance of stationary phase E. coli[60] possibly 
due to reliance on L,D-transpeptidase-catalysed 3,3 crosslink-
ing[25] and peptidoglycan precursor accumulation competing 
with penicillin for the PBP active sites.   
Muramyl meso-DAP tripeptide also attenuated ampicillin in-
hibition (Figure 5a), suggesting acceptor alone bound E. coli 
PBP1B.   Similarly, Streptomyces R61 D,D-transpeptidase in-
hibition by penicillin V was weakened by a meso-DAP accep-
tor[59].   Methylene lipid II-Lys or ampicillin inhibition and our 
kinetic analysis of PBP1B (Figure 5a-h) suggested transpepti-
dase acceptor and transglycosylase/transpeptidase donor were 
bound as a ternary complex pre-transpeptidation, relating 
transglycosylase site lipid II binding to transpeptidase site ac-
ceptor binding.   A related complex was proposed by Frere et 
al.[61,62] for Streptomyces R61 transpeptidase.   
The reciprocal increase of the affinity of PBP1B for donor in 
the presence of acceptor and vice versa where here, KLII < 
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KLII and KM3P < KM3P, as revealed by our kinetic mechanistic 
studies (Figure 5d-h) was consistent with acceptor-mediated 
increase in inhibitory potency of methylene lipid II-Lys (Fig-
ure 5c).  Although our kinetic data were most consistent with 
PBP1B transpeptidation proceeding via a random rapid equi-
librium kinetic mechanism (S.2.3.; Table S8, Figures 5d-g and 
S13), discrimination between this and an ordered steady state 
mechanism (which has the same form as equation 3[28]) will 
have to await more extensive product inhibition studies.   
We observed detectable amounts of PBP1B-catalysed D-ala-
nine release from lipid II-Lys alone (Figure S5b and Table S6).  
Although this is consistent with donor binding within a random 
or an ordered mechanism of catalysis, this activity was very 
low (e.g. Figure 1e,f and 4e), relative to PBP1B transpepti-
dation.  Therefore, clearly the formation of a ternary complex 
of donor and acceptor with enzyme was obligatory for full ex-
pression of donor acylation as reported by D-alanine release. 
Our data suggest PBP1B avoids loss of donor peptides through 
unnecessary D,D-carboxypeptidation, maintaining efficiency 
of peptidoglycan synthesis (Figure 1e,f, Figure S5b). Our data 
(Figure 5a-h) are consistent with transglycosylation generating 
polymer, which with a bound acceptor, may be diverted to the 
transpeptidation site.  Our data open up the possibility of gen-
erating potent PBP inhibitors incorporating aspects of both do-
nor and acceptor substrates. 
 
CONCLUSIONS 
In this paper we have developed a continuous spectrophoto-
metric method for the analysis of E. coli PBP1B activity.  Alt-
hough this has potential utility in the search for new antimicro-
bials that target PBPs, this technique was instrumental in un-
covering hitherto undiscovered interactions between the en-
zyme and its peptidoglycan substrates responsible for recogni-
tion of peptidoglycan strands that would facilitate their suc-
cessful crosslinking by transpeptidation. We also observed ef-
fective discrimination against stereochemically erroneous pep-
tidoglycan substrates whose incorporation might compromise 
peptidoglycan synthesis, an observation whose physiological 
significance is underscored by the fact that L,L-DAP is the di-
rect precursor of meso-DAP in vivo[27].    The findings reported 
here also addressed the impact of competing peptidoglycan 
precursors on the sensitivity of a -lactam antibiotic for its tar-
get.  This implies that flux through the peptidoglycan pathway 
may in part control the antibacterial killing exerted by these 
antibiotics and point to potential utility of co-administration of 
drugs that target not only PBP transpeptidases but also the en-
zymes that supply their donor substrates.  Finally, it is an aspi-
ration that the technology developed with respect to the gener-
ation of the peptidoglycan substrates used in this study might 
provide a useful resource supporting research in the field of 




Spectrophotometric PBP1B Assays.   The E. coli PBP1B 
transpeptidase assay was designed to follow PBP-catalysed re-
lease of D-alanine which was oxidised by D-amino acid oxi-
dase producing hydrogen peroxide which was consumed by 
horse radish peroxidase, which with the chromogen amplex 
red, formed the dye resorufin (7-hydroxy-3H-phenoxazin-3-
one), to establish a continuous assay for PBP activity.  Where 
assays involved release of L-alanine, its conversion to D-ala-
nine by alanine racemase, facilitated its detection by the D-
amino acid oxidase/horse radish peroxidase couple. Coupling 
enzymes (D-amino acid oxidase, horse radish peroxidase, ala-
nine racemase) were assayed as described in the S.1.2.6. Anal-
ysis of enzyme kinetic data was performed using GraphPad 
Prizm vers. 8 or MATLAB 2017a (S.1.2.8.).  
Continuous and discontinuous spectrophotometric E. coli 
PBP1B transpeptidation activity assay.  All spectrophoto-
metric measurements were performed using a Cary 100 UV/vis 
spectrophotometer equipped with a 12-place Peltier thermo-
statically controlled cell changer (Agilent).  Data were col-
lected at 30°C using Hellma 1 cm pathlength micro quartz cu-
vettes with blacked out faces apart from an 8 mm x 2 mm win-
dow.  Data were acquired every 0.1 seconds, with the spectro-
photometer operating with a 1 cm slit bandwidth.  The assay 
was configured to follow D-alanine release continuously in a 
final volume  of 175 l to 200 l of 50 mM bis-Tris propane 
pH 8.5, 20 mM MgCl2, 0.13% (v/v) Triton X-100, 50 M am-
plex Red, 36.1 unit (U).ml-1 R. gracilis  D-amino acid oxidase, 
14.3 U.ml-1 horse radish peroxidase (units as defined in 
S.1.2.6.1. and S.1.2.6.3.), 1.97 M LpoB, lipid II donor, ac-
ceptor (both as specified in the text), and E. coli PBP 1B 
freshly diluted into 25 mM Tris, 0.2% (v/v) Triton X-100, 10% 
(v/v) glycerol pH 7.5.    Assays were pre-incubated with either 
donor or acceptor for two minutes, at which point, the PBP was 
added.  After a further six minutes, the final assay component 
(acceptor or donor) was added to initiate transpeptidation.   As-
says followed the increase in absorbance of resorufin at 555 
nm (Resorufin 1cm, 555 nm = 54,000 M
-1.cm-1[63]). 
 To follow L-alanine release in real time, the above continuous 
assay was additionally supplemented with 15.01 U.ml-1 E. coli 
alanine racemase (unit defined in S.1.2.6.2.) to convert L-ala-
nine to its D-stereoisomer which could be detected via the D-
amino acid oxidase/horse radish peroxidase couple.   Alterna-
tively, a discontinuous method was developed where in a final 
volume of 196 l, 50 mM bis-Tris propane pH 8.5, 20 mM 
MgCl2, 0.13% (v/v) Triton X-100, 1.97 M LpoB, 20 M lipid 
II-Lys donor (C-terminal L-alanine or D-alanine), 20 M Mur-
NAc meso-DAP pentapeptide acceptor and 34.4 nM E. coli 
PBP 1B added from a freshly diluted stock in 25 mM Tris, 
0.2% (v/v) Triton X-100, 10% (v/v) glycerol, pH 7.5 were in-
cubated for 1 hour.  The assay was terminated by addition 2.86 
mM ampicillin and supplemented with 50 l of 50 mM bis-
Tris propane, pH 8.5, 14.45 U.ml-1 R. gracilis D-amino acid 
oxidase, 5.71 U.ml-1 horse radish peroxidase, 0.075 U.ml-1 E. 
Page 13 of 16
ACS Paragon Plus Environment































































coli alanine racemase, 0.1 mM pyridoxal phosphate, and 0.8 
mM Amplex Red.  The absorbance at 555 nm was followed 
until completion.  Assay function was established by spiking 
assays that returned negative results with 5 M L-alanine. 
 
ASSOCIATED CONTENT  
Material sources, protein analytical methods, purification 
methodologies for PBP1B, LpoB, DacB and alanine racemase 
from  E. coli and D-amino acid oxidase from R. gracilis, mass 
spectrometric methods, preparation of transpeptidase donor 
and acceptor substrates, spectrophotometric and other enzyme 
assays and global non-linear analysis of kinetic data are rec-
orded in Supplementary Data sections  S.1.1., S.1.2.1., 
S.1.2.2., S.1.2.3., S.1.2.4., S.1.2.5., S.1.2.6., S.1.2.7. and 
S.1.2.8. whilst Supplementary Results, References, Tables, F 
igures and their legends are recorded in  Supplementary Data 
sections  S.2. to S.7. inclusive.  This material is available free 
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